Powering a trial for superiority can be financially risky. In some instances it may also prove unnecessary.
Why You Should Not Power for Superiority Upfront: Promising Zone Clinical Trials with "Adaptive Switch"
Jun 26, 2015 12:00:06 PM
Apr 30, 2015 5:00:00 PM
Adaptive financing (not to be confused with adaptive licensing) explores how biotechs, pharmaceuticals and potential investors, can use adaptive designs for more strategic financial decision-making, as well as for efficient drug development.
“For example,” writes Zoran Antonijevic, Senior Director at Cytel Consulting, “Reduction in costs and development time can be accomplished by combining...